The P50 Research Center in Perioperative Sciences: How the investment by the National Institute of General Medical Sciences in team science has reduced postburn mortality.

J Trauma Acute Care Surg

From the Department of Surgery (C.C.F., K.D.C., C.V., G.H., J.C.-D., C.P., L.E.S., A.E.A., R.Z.-S., A.N.G., O.E.S., D.N.H.) and Institute for Translational Sciences (C.C.F., C.V., A.N.G., D.N.H.), University of Texas Medical Branch, Galveston, Texas; and Shriners Hospitals for Children (C.C.F., K.D.C., C.V., G.H., J.C.-D., C.P., L.E.S., A.E.A., R.Z.-S., A.N.G., O.E.S., D.N.H.), Galveston, Texas.

Published: September 2017

Since the inception of the P50 Research Center in Injury and Peri-operative Sciences (RCIPS) funding mechanism, the National Institute of General Medical Sciences has supported a team approach to science. Many advances in critical care, particularly burns, have been driven by RCIPS teams. In fact, burns that were fatal in the early 1970s, prior to the inception of the P50 RCIPS program, are now routinely survived as a result of the P50-funded research. The advances in clinical care that led to the reduction in postburn death were made by optimizing resuscitation, incorporating early excision and grafting, bolstering acute care including support for inhalation injury, modulating the hypermetabolic response, augmenting the immune response, incorporating aerobic exercise, and developing antiscarring strategies. The work of the Burn RCIPS programs advanced our understanding of the pathophysiologic response to burn injury. As a result, the effects of a large burn on all organ systems have been studied, leading to the discovery of persistent dysfunction, elucidation of the underlying molecular mechanisms, and identification of potential therapeutic targets. Survival and subsequent patient satisfaction with quality of life have increased. In this review article, we describe the contributions of the Galveston P50 RCIPS that have changed postburn care and have considerably reduced postburn mortality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573648PMC
http://dx.doi.org/10.1097/TA.0000000000001644DOI Listing

Publication Analysis

Top Keywords

p50 center
8
national institute
8
institute general
8
general medical
8
medical sciences
8
reduced postburn
8
postburn mortality
8
inception p50
8
p50 rcips
8
rcips
5

Similar Publications

Article Synopsis
  • This study focuses on PRT543, a new oral medication designed to inhibit PRMT5, an enzyme implicated in the growth of certain blood cancers.
  • It specifically investigates the effects of PRT543 in patients suffering from advanced myeloid malignancies that have mutations in splicing factors, which are crucial for proper gene expression and can contribute to cancer progression.
  • The early Phase Ib trial aims to assess the safety, tolerability, and initial effectiveness of PRT543 in these patients, providing groundwork for potential future treatments.
View Article and Find Full Text PDF

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.

NPJ Breast Cancer

January 2025

Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillmann Cancer Center, Pittsburgh, PA, USA.

Special histologic subtypes of breast cancer (BC) exhibit unique phenotypes and molecular profiles with diagnostic and therapeutic implications, often differing in behavior and clinical trajectory from common BC forms. Novel methodologies, such as artificial intelligence may improve classification. Genetic predisposition plays roles in a subset of cases.

View Article and Find Full Text PDF

Purpose: Determine if molecular classification using mismatch repair (MMR) and p53 protein expression predicts recurrence-free survival (RFS) and overall survival (OS) in endometrial cancer (EC) patients treated with chemotherapy and radiation (CRT) versus chemotherapy (CT).

Methods: GOG-0258, a phase III randomized trial (NCT00942357), compared CRT to CT. Immunohistochemistry assessed MMR and p53 status.

View Article and Find Full Text PDF

Background: The neuropathologies of Alzheimer's disease (AD) and Lewy body disease (LBD) commonly co-occur. Parkinsonism is the hallmark feature in LBD but it can be difficult to predict the presence of these co-pathologies early in the course of clinical disease. Timely diagnosis has crucial implications, especially with the advent of disease-modifying therapies.

View Article and Find Full Text PDF

DICER1-associated sarcoma is an emerging entity, defined by either somatic or germline dicer 1, ribonuclease III (DICER1) mutations and sharing characteristic morphologic features irrespective of the site of origin. In addition to the DICER1 driver mutation, concurrent genomic alterations, including tumor protein 53 (TP53) inactivation and RAS pathway activation, are frequently detected. Tumors that morphologically resemble malignant peripheral nerve sheath tumor (MPNST) have rarely been reported among DICER1 sarcomas and often pose diagnostic challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!